Werewolf Therapeutics (HOWL) Leases (2021 - 2025)
Werewolf Therapeutics (HOWL) has disclosed Leases for 5 consecutive years, with $5.4 million as the latest value for Q3 2025.
- On a quarterly basis, Leases fell 12.24% to $5.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.4 million, a 12.24% decrease, with the full-year FY2024 number at $6.0 million, down 12.88% from a year prior.
- Leases was $5.4 million for Q3 2025 at Werewolf Therapeutics, down from $5.6 million in the prior quarter.
- In the past five years, Leases ranged from a high of $13.4 million in Q4 2021 to a low of $2.0 million in Q3 2021.
- A 5-year average of $6.8 million and a median of $6.5 million in 2024 define the central range for Leases.
- Biggest YoY gain for Leases was 386.07% in 2022; the steepest drop was 36.9% in 2022.
- Werewolf Therapeutics' Leases stood at $13.4 million in 2021, then plummeted by 36.9% to $8.5 million in 2022, then dropped by 18.61% to $6.9 million in 2023, then fell by 12.88% to $6.0 million in 2024, then decreased by 9.65% to $5.4 million in 2025.
- Per Business Quant, the three most recent readings for HOWL's Leases are $5.4 million (Q3 2025), $5.6 million (Q2 2025), and $5.8 million (Q1 2025).